Jubilant Pharmova. has filed a patent for a method of treating and preventing diseases associated with NETosis. The method involves administering a compound, such as Formula (I) or its derivatives, to a subject. The compound can be used in the treatment and prevention of NETosis-related conditions. GlobalData’s report on Jubilant Pharmova gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Jubilant Pharmova Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jubilant Pharmova, Graphene oxide composites was a key innovation area identified from patents. Jubilant Pharmova's grant share as of September 2023 was 33%. Grant share is based on the ratio of number of grants to total number of patents.

The patent filed is for a method of treating netosis

Source: United States Patent and Trademark Office (USPTO). Credit: Jubilant Pharmova Ltd

A recently filed patent (Publication Number: US20230293509A1) describes a method for treating and/or preventing diseases or disorders associated with NETosis, a process involving the release of neutrophil extracellular traps (NETs). The method involves administering a compound selected from a specific group of compounds to a subject. These compounds include various derivatives and compositions thereof. The diseases or disorders that can be treated or prevented using this method include cancer, cancer metastasis, immune disorders, inflammatory disorders, and transplant rejection, among others.

The patent claims also specify that the method can be used to treat specific conditions such as systemic inflammatory response syndrome, acute lung injury, acute respiratory distress syndrome, COVID-19 related lung infection, sepsis, stroke, brain injuries, chronic kidney disease, diabetes, thrombosis, lupus, rheumatoid arthritis, pulmonary diseases, inflammatory bowel disease, and Alzheimer's disease, among others.

Furthermore, the patent claims mention that the method can be used to treat specific types of cancer, including breast cancer, prostate cancer, pancreatic cancer, gastric cancer, lung cancer, colon cancer, liver cancer, kidney cancer, ovarian cancer, and various types of leukemia and lymphoma. The method can also be used to treat cancer metastasis, such as liver cancer metastasis, lung cancer metastasis, and omentum cancer metastasis.

The compounds mentioned in the patent claims can be administered alone or in combination with other clinically relevant cytotoxic agents, immune modulator agents, or anti-inflammatory agents. The compounds can be formulated into various pharmaceutical compositions, such as tablets, capsules, powders, syrups, solutions, aerosols, or suspensions.

Overall, this patent describes a method for treating and preventing diseases or disorders associated with NETosis using specific compounds. The method has potential applications in various fields, including cancer treatment, immune disorders, and inflammatory conditions. Further research and development may be required to validate the efficacy and safety of these compounds in clinical settings.

To know more about GlobalData’s detailed insights on Jubilant Pharmova, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies